US 11,053,199 B2
Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof
Lianfeng Huang, Basking Ridge, NJ (US); Nancy Tsou, Edison, NJ (US); Nicole Suzanne White, San Diego, CA (US); Jun Xu, Suzhou (CN); and Qun Zhang, Suzhou (CN)
Assigned to Celgene Corporation, Summit, NJ (US); and Abide Therapeutics, Inc., San Diego, CA (US)
Filed by Celgene Corporation, Summit, NJ (US); and Abide Therapeutics, Inc., San Diego, CA (US)
Filed on Sep. 12, 2019, as Appl. No. 16/569,578.
Claims priority of provisional application 62/731,014, filed on Sep. 13, 2018.
Prior Publication US 2020/0095201 A1, Mar. 26, 2020
Int. Cl. C07D 211/94 (2006.01); A61P 35/00 (2006.01)
CPC C07D 211/94 (2013.01) [A61P 35/00 (2018.01); C07B 2200/13 (2013.01)] 15 Claims
 
1. Crystalline Form A of (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, having an X-ray powder diffraction pattern comprising peaks at 18.1, 20.1, and 22.3 degrees 2θ±0.2 degrees 2θ.